GlassScriptPhysician profile
Kani M Brown
NPI 1568750669
$4,049.79
in general payments reported to CMS, 2019-2025
23 companies · $922 in 2025
The $922 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $167 · 2021: $285 · 2022: $690 · 2023: $906 · 2024: $659 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.07 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $1,014.09 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $346.66 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $247.92 | 2020-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $239.66 | 2019-2021 | |
| Lumenis Be INC | $237.80 | 2025 | Optilight |
| Abbvie INC. | $222.61 | 2022-2023 | Durysta, Vuity, Restasis Multidose |
| Alcon Vision LLC | $212.16 | 2022-2025 | Precision7, Precision 7, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.47 | 2019-2021 | |
| Allergan, INC. | $189.63 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $187.40 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $175.05 | 2021-2023 | |
| Dompe US, INC. | $159.14 | 2021-2025 | Oxervate |
| Glaukos Corporation | $150.00 | 2025 | Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $116.77 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $84.36 | 2019-2024 | Lipiflow System Activator II (Disposable |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $49.00 | 2020-2023 | Clariti Contact Lens |
| Eyevance Pharmaceuticals LLC | $47.68 | 2019-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $42.55 | 2022 | |
| Mallinckrodt Hospital Products INC. | $41.67 | 2024-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $27.81 | 2023 | Acuvue |
| Shire North American Group INC | $23.17 | 2019 | |
| Sight Sciences, INC. | $17.89 | 2022 | |
| Astellas Pharma US INC | $16.30 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kani Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.